Amano Tsukuru, Murakami Atsushi, Murakami Takashi, Chano Tokuhiro
Department of Obstetrics & Gynecology, Shiga University of Medical Science, Tsukinowa-cho, Seta, Otsu, Shiga 520-2192, Japan.
Department of Clinical Laboratory Medicine and Medical Genetics, Shiga University of Medical Science, Tsukinowa-cho, Seta, Otsu, Shiga 520-2192, Japan.
Antioxidants (Basel). 2021 Jan 28;10(2):187. doi: 10.3390/antiox10020187.
Ovarian clear cell carcinomas (OCCCs) are resistant to conventional anti-cancer drugs; moreover, the prognoses of advanced or recurrent patients are extremely poor. OCCCs often arise from endometriosis associated with strong oxidative stress. Of note, the stress involved in OCCCs can be divided into the following two categories: (a) carcinogenesis from endometriosis to OCCC and (b) factors related to treatment after carcinogenesis. Antioxidants can reduce the risk of OCCC formation by quenching reactive oxygen species (ROS); however, the oxidant stress-tolerant properties assist in the survival of OCCC cells when the malignant transformation has already occurred. Moreover, the acquisition of oxidative stress resistance is also involved in the cancer stemness of OCCC. This review summarizes the recent advances in the process and prevention of carcinogenesis, the characteristic nature of tumors, and the treatment of post-refractory OCCCs, which are highly linked to oxidative stress. Although therapeutic approaches should still be improved against OCCCs, multi-combinatorial treatments including nucleic acid-based drugs directed to the transcriptional profile of each OCCC are expected to improve the outcomes of patients.
卵巢透明细胞癌(OCCCs)对传统抗癌药物具有耐药性;此外,晚期或复发患者的预后极差。OCCCs常起源于与强烈氧化应激相关的子宫内膜异位症。值得注意的是,OCCCs所涉及的应激可分为以下两类:(a)从子宫内膜异位症到OCCC的致癌过程,以及(b)致癌后的治疗相关因素。抗氧化剂可通过淬灭活性氧(ROS)降低OCCC形成的风险;然而,当恶性转化已经发生时,抗氧化应激特性有助于OCCC细胞的存活。此外,获得抗氧化应激抗性也与OCCC的癌症干性有关。本综述总结了与氧化应激高度相关的致癌过程和预防、肿瘤特征以及难治性OCCCs治疗方面的最新进展。尽管针对OCCCs的治疗方法仍需改进,但包括针对每个OCCC转录谱的核酸类药物在内的多组合治疗有望改善患者的治疗效果。